Will Stone
👤 SpeakerAppearances Over Time
Podcast Appearances
Much of the recent work on psychedelics has focused on people with serious mental illness.
This study, on the other hand, included volunteers with no underlying conditions who had never taken the drug before.
They were given a single dose of 25 milligrams, strong enough to provoke a psychedelic trip.
The research team looked at brain activity.
They linked greater diversity of neural activity to increased psychological insights after the trip and ultimately improvements in a sense of well-being a month later.
The study authors say the findings need to be replicated in larger studies, but they may help explain the beneficial effects of the drug.
Psilocybin could be up for FDA approval for treating depression in the near future.
Much of the recent work on psychedelics has focused on people with serious mental illness.
This study, on the other hand, included volunteers with no underlying conditions who had never taken the drug before.
They were given a single dose of 25 milligrams, strong enough to provoke a psychedelic trip.
The research team looked at brain activity.
They linked greater diversity of neural activity to increased psychological insights after the trip and ultimately improvements in a sense of well-being a month later.
The study authors say the findings need to be replicated in larger studies, but they may help explain the beneficial effects of the drug.
Psilocybin could be up for FDA approval for treating depression in the near future.
Researchers at Hopkins used artificial intelligence to analyze more than 40,000 public comments submitted to the federal government.
That was in response to a proposal by the Drug Enforcement Administration in 2024 to reschedule cannabis.
About a third wanted to move cannabis from a Schedule 1, the most restrictive category, to Schedule 3.
About two-thirds thought the federal government should go even further, with some saying it should not be a controlled substance at all.